Bimagrumab – Research and Therapeutic-Grade ActRII Inhibitor
Overview
Bimagrumab is a monoclonal antibody targeting the activin type II receptor (ActRII), developed by Eli Lilly for obesity, metabolic disorders, and muscle-wasting conditions. Unlike GLP-1 receptor agonists, Bimagrumab operates through a dual mechanism of fat reduction and muscle growth, making it a promising candidate for advanced metabolic research and therapeutic development.
Key Features
- Active Ingredient: Bimagrumab (anti-ActRII monoclonal antibody)
- Formulation: Injectable solution, research and therapeutic grade
- Mechanism: Inhibition of ActRII signaling, promoting skeletal muscle growth and fat reduction
- Indications (Research/Development): Obesity, overweight management, sarcopenia, metabolic disorders
- Developer:ShiLai™Peptide
Mechanism of Action
Bimagrumab binds to ActRII receptors, blocking the negative regulatory signaling that inhibits muscle growth. Its key effects include:
- Enhanced skeletal muscle mass
- Targeted fat reduction, especially visceral adipose tissue
- Improved metabolic profile, supporting research into obesity and diabetes interventions
BELIEVE Study (Phase IIb)
- Design: Combined Bimagrumab with GLP-1 therapy (Semaglutide)
- Population: Adults with obesity
- Results:
- Average body weight reduction: 22.1% with combination therapy
- Fat mass reduction: 92.8% of weight loss
- Compared to Semaglutide alone: 15.7% weight reduction, 71.8% fat mass
- Safety Profile: Well tolerated, with mild-to-moderate infusion-related reactions reported in a minority of patients